• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

Hepatitis Blog Archives

All | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Read an HHS Blog.
Liver Meeting
Progress Report 2012
Partners share an update on Viral Hepatitis Action Plan progress.
DC Convention
Drs. Ron Valdiserri, Ellie McCance-Katz, and John Ward dicussing federal viral hepatitis initiatives with Viral Hepatitis Prevention Coordinators from across the country.
Ronald Valdiserri
Throughout September’s observance of National Recovery Month, individuals, organizations, and communities across the nation celebrated recovery from mental health issues and addiction challenges.
Meico Whitlock
Last month, the National Alliance of State and Territorial AIDS Directors (NASTAD) attended the fourth annual Plain Talk in Complex Times conference in Arlington, Virginia.
FDA logo
On September 25, 2013, the Food and Drug Administration (FDA) issued a Drug Safety Communication announcing that the FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection.
VHAP renewal group
Building on these important activities, all of the federal partners will work to refine and finalize our respective actions for the renewed plan over the coming weeks.
AIDS.gov

Pages

  • of 5
  • >